Related Experiment Video
Updated: Apr 16, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Pharmacogenomics and targeted therapy of cancer: Focusing on non-small cell lung cancer
Seyyed Mortaza Haghgoo1, Abdolamir Allameh1, Esmaeil Mortaz2
1Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Abstract:
Recent studies have been established high degree of genetic diversity in solid organ tumors among individuals and even between individual tumor cells. This intratumor and intertumor genetic diversity results in a heterogeneous tumor with unique characteristics which potentially allows effective drug therapy. The goal of pharmacogenomics is to elucidate the genetic network(s) that underlie drug efficacy and drug resistance. Advances in targeted and personalized therapy play an increasingly important role in many common cancers, notably lung cancer, due to the high incidence, prevalence, mortality and the greater tendency towards drug resistance seen in these patients. Non-small cell lung cancer (NSCLC) is characterized by mutations in the epidermal growth factor receptor (EGFR) and or downstream kinase pathways. This has led to the development of highly selective monoclonal antibodies and EGFR tyrosine kinase inhibitors (EGFR-TKIs) to prevent cancer initiation, proliferation, differentiation, angiogenesis, survival, and invasion. However, resistance to many of these new treatments is induced and further pharmacogenomic analysis has revealed mutations associated with increased or reduced drug efficacy. Combinations of kinase inhibitors or potentially the targeting of cancer stem cells may further increase the success of pharmacogenomics in treating patients with lung cancer.
Insights
Genetic diversity in tumors drives personalized medicine. Pharmacogenomics in non-small cell lung cancer (NSCLC) targets drug resistance, improving treatment efficacy through genetic analysis.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Tumor genetic diversity influences individual patient outcomes and treatment responses.
- Pharmacogenomics aims to understand genetic factors affecting drug efficacy and resistance.
- Targeted therapies and personalized medicine are crucial for managing common cancers like lung cancer.
Purpose of the Study:
- To explore the role of pharmacogenomics in overcoming drug resistance in non-small cell lung cancer (NSCLC).
- To investigate how genetic diversity within tumors impacts treatment strategies.
- To identify genetic markers associated with drug efficacy and resistance in NSCLC patients.
Main Methods:
- Analysis of genetic diversity in solid organ tumors, including intratumor and intertumor heterogeneity.
- Review of pharmacogenomic studies focusing on drug efficacy and resistance mechanisms.
- Examination of mutations in EGFR and downstream pathways in NSCLC.
Main Results:
- Genetic diversity in tumors presents opportunities for tailored drug therapies.
- Mutations in EGFR and related pathways are key in NSCLC, leading to targeted therapies like EGFR-TKIs.
- Drug resistance mechanisms are increasingly understood through pharmacogenomic analysis, revealing associated mutations.
Conclusions:
- Pharmacogenomic analysis is vital for developing effective treatments for NSCLC.
- Understanding tumor genetic heterogeneity is essential for personalized cancer therapy.
- Future strategies may involve combination therapies or targeting cancer stem cells to enhance treatment success.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
01:29Pharmacogenetics and Pharmacogenomics: Overview
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies